Analysts are on the Bearish side about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) this week.

February 15, 2018 - By Maria Brooks

 Analysts are on the Bearish side about Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) this week.
Investors sentiment decreased to 1.36 in Q3 2017. Its down 0.10, from 1.46 in 2017Q2. It dropped, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported.
Citigroup has invested 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Citadel Advsr Limited Liability Company holds 23,050 shares. Geode Capital Llc invested in 998,697 shares or 0% of the stock. State Of Wisconsin Inv Board invested in 79,000 shares. Kansas-based Creative Planning has invested 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). California Public Employees Retirement Systems has 160,600 shares for 0% of their portfolio. Royal Comml Bank Of Canada stated it has 21,719 shares. Point72 Asset Mngmt Lp accumulated 0% or 400,000 shares. Balyasny Asset Mngmt Lc owns 17,916 shares for 0% of their portfolio. Ameritas Invest Ptnrs has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 7,586 shares. Legal And General Grp Public Limited Company has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 29,020 shares. Amer Intll Gru owns 72,387 shares for 0% of their portfolio. Guggenheim Capital Ltd Liability Corp invested in 0% or 42,712 shares. Manufacturers Life Ins The, Ontario – Canada-based fund reported 90,620 shares. State Street Corp owns 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 1.88M shares.

Since October 26, 2017, it had 1 insider purchase, and 2 insider sales for $7.00 million activity. BAKER BROS. ADVISORS LP had bought 8.00M shares worth $12.00 million.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Buy” rating by Piper Jaffray on Thursday, November 9. The stock of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) earned “Outperform” rating by Wedbush on Wednesday, February 1. The firm has “Outperform” rating by Wedbush given on Wednesday, January 6. On Thursday, November 16 the stock rating was maintained by H.C. Wainwright with “Buy”. Piper Jaffray maintained Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) rating on Monday, September 11. Piper Jaffray has “Buy” rating and $4.0 target. Below is a list of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) latest ratings and price target changes.

16/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4 Initiates Coverage On
11/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain

The stock decreased 4.50% or $0.09 during the last trading session, reaching $1.91. About 552,937 shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 15, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $373.66 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

More recent Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) news were published by: Fool.com which released: “Why II-VI, Sanmina, and Idera Pharmaceuticals Slumped Today” on January 22, 2018. Also Globenewswire.com published the news titled: “BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine …” on January 22, 2018. Businesswire.com‘s news article titled: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Idera …” with publication date: January 22, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.